Cellectis SA
CLLS4.860USD
+0.170+3.62%
Market hours （ET）Quotes delayed by 15 min
351.50MMarket Cap
LossP/E TTM
More Details of Cellectis SA Company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA Info
Ticker SymbolCLLS
Company nameCellectis SA
IPO dateFeb 06, 2007
CEOSourdive (David J.D)
Number of employees224
Security typeDepository Receipt
Fiscal year-endFeb 06
Address8, rue de la Croix Jarry
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75013
Phone33181691600
Websitehttps://www.cellectis.com/
Ticker SymbolCLLS
IPO dateFeb 06, 2007
CEOSourdive (David J.D)
Company Executives of Cellectis SA
Name
Name/Position
Position
Shareholding
Change
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
Nomura Investment Management Business Trust
0.31%
Bellecapital AG
0.31%
Other
87.15%
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
Nomura Investment Management Business Trust
0.31%
Bellecapital AG
0.31%
Other
87.15%
Shareholder Types
Shareholders
Proportion
Investment Advisor
7.22%
Hedge Fund
6.09%
Investment Advisor/Hedge Fund
0.42%
Research Firm
0.22%
Other
86.06%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
70
10.10M
29.55%
--
2025Q3
77
10.10M
29.65%
-3.45M
2025Q2
79
13.55M
35.05%
-1.95M
2025Q1
82
15.50M
31.47%
-7.25M
2024Q4
86
16.67M
24.79%
+2.93M
2024Q3
104
15.35M
28.39%
+1.55M
2024Q2
103
13.80M
26.34%
-48.27K
2024Q1
112
13.82M
26.53%
-5.23M
2023Q4
124
13.74M
31.43%
+147.34K
2023Q3
142
13.59M
44.11%
-2.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Long Focus Capital Management LLC
4.72M
6.52%
--
--
Jun 30, 2025
B Group, Inc.
3.26M
4.5%
--
--
Jun 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
Nomura Investment Management Business Trust
226.88K
0.31%
--
--
Jun 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jan 31, 2025
LPL Financial LLC
85.66K
0.12%
+915.00
+1.08%
Jun 30, 2025
Morgan Stanley & Co. International Plc
73.19K
0.1%
+6.00K
+8.93%
Jun 30, 2025
Millennium Management LLC
35.66K
0.05%
-68.19K
-65.66%
Jun 30, 2025
AllianceBernstein L.P.
54.64K
0.08%
+32.83K
+150.56%
Jun 30, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Avantis International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cellectis SA?
The top five shareholders of Cellectis SA are:
Long Focus Capital Management LLC holds 4.72M shares, accounting for 6.52% of the total shares.
B Group, Inc. holds 3.26M shares, accounting for 4.50% of the total shares.
UBS Asset Management Switzerland AG holds 1.44M shares, accounting for 1.99% of the total shares.
Nomura Investment Management Business Trust holds 226.88K shares, accounting for 0.31% of the total shares.
Bellecapital AG holds 226.07K shares, accounting for 0.31% of the total shares.
Long Focus Capital Management LLC holds 4.72M shares, accounting for 6.52% of the total shares.
B Group, Inc. holds 3.26M shares, accounting for 4.50% of the total shares.
UBS Asset Management Switzerland AG holds 1.44M shares, accounting for 1.99% of the total shares.
Nomura Investment Management Business Trust holds 226.88K shares, accounting for 0.31% of the total shares.
Bellecapital AG holds 226.07K shares, accounting for 0.31% of the total shares.
What are the top three shareholder types of Cellectis SA?
The top three shareholder types of Cellectis SA are:
Long Focus Capital Management LLC
B Group, Inc.
UBS Asset Management Switzerland AG
Long Focus Capital Management LLC
B Group, Inc.
UBS Asset Management Switzerland AG
How many institutions hold shares of Cellectis SA (CLLS)?
As of 2025Q4, 70 institutions hold shares of Cellectis SA, with a combined market value of approximately 10.10M, accounting for 29.55% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.10%.
What is the biggest source of revenue for Cellectis SA?
In FY2024, the -- business generated the highest revenue for Cellectis SA, amounting to -- and accounting for --% of total revenue.
